0.274 -0.005 (-1.79%) | 02-06 11:32 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() ![]() ![]() |
|||
Targets | 6-month : | 0.35 | 1-year : | 0.4 |
Resists | First : | 0.3 | Second : | 0.35 |
Pivot price | 0.26 ![]() |
|||
Supports | First : | 0.25 | Second : | 0.23 |
MAs | MA(5) : | 0.27 ![]() |
MA(20) : | 0.26 ![]() |
MA(100) : | 0.25 ![]() |
MA(250) : | 0.82 ![]() |
|
MACD | MACD : | 0 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 61.3 ![]() |
D(3) : | 54.9 ![]() |
RSI | RSI(14): 52.9 ![]() |
|||
52-week | High : | 3.38 | Low : | 0.14 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ GLYC ] has closed below upper band by 29.2%. Bollinger Bands are 65.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 16 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 0.29 - 0.29 | 0.29 - 0.29 |
Low: | 0.26 - 0.26 | 0.26 - 0.26 |
Close: | 0.28 - 0.28 | 0.28 - 0.28 |
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Sat, 01 Feb 2025
GlycoMimetics executives to depart amid merger plans - MSN
Wed, 06 Nov 2024
GlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual Meeting - Business Wire
Wed, 06 Nov 2024
GlycoMimetics to Present Major AML Drug Trial Data at ASH 2024 Conference - StockTitan
Wed, 30 Oct 2024
GlycoMimetics Announces Merger with Crescent Biopharma - Yahoo Finance
Wed, 30 Oct 2024
GlycoMimetics To Acquire Crescent Biopharma - FinSMEs
Tue, 29 Oct 2024
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of Shareholders - PR Newswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 65 (M) |
Held by Insiders | 4.253e+007 (%) |
Held by Institutions | 3.1 (%) |
Shares Short | 1,640 (K) |
Shares Short P.Month | 0 (K) |
EPS | -4.078e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -408 % |
Return on Assets (ttm) | 770.5 % |
Return on Equity (ttm) | -59.3 % |
Qtrly Rev. Growth | 10000 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -56.79 |
EBITDA (p.s.) | 5434.78 |
Qtrly Earnings Growth | -0.7 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -36 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.01 |
Price to Cash Flow | 0.84 |
Dividend | 0 |
Forward Dividend | 5.64e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |